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A B S T R A C TBackground: Patients, physicians, and other decision makers make
implicit but inevitable trade-offs among risks and beneﬁts of treat-
ments. Many methods have been proposed to promote transparent
and rigorous beneﬁt-risk analysis (BRA). Objective: To propose a
framework for classifying BRA methods on the basis of key factors
that matter most for patients by using a common mathematical
notation and compare their results using a hypothetical example.
Methods: We classiﬁed the available BRA methods into three catego-
ries: 1) unweighted metrics, which use only probabilities of beneﬁts
and risks; 2) metrics that incorporate preference weights and that
account for the impact and duration of beneﬁts and risks; and 3)
metrics that incorporate weights based on decision makers’ opinions.
We used two hypothetical antiplatelet drugs (a and b) to compare the
BRA methods within our proposed framework. Results: Unweighted
metrics include the number needed to treat and the number needed
to harm. Metrics that incorporate preference weights include thoseee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2014.11.001
deh@partners.org.
ndence to: Mehdi Najafzadeh, Department of Medic
n’s Hospital and Harvard Medical School, Bostonthat use maximum acceptable risk, those that use relative-value–
adjusted life-years, and those that use quality-adjusted life-years.
Metrics that use decision makers’ weights include the multicriteria
decision analysis, the beneﬁt-less-risk analysis, Boers’ 3 by 3 table, the
Gail/NCI method, and the transparent uniform risk beneﬁt overview.
Most BRA methods can be derived as a special case of a generalized
formula in which some are mathematically identical. Numerical
comparison of methods highlights potential differences in BRA results
and their interpretation. Conclusions: The proposed framework pro-
vides a uniﬁed, patient-centered approach to BRA methods classiﬁca-
tion based on the types of weights that are used across existing
methods, a key differentiating feature.
Keywords: beneﬁt-risk analysis, harm-beneﬁt analysis.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Beneﬁt-risk analysis (BRA) is a formal approach for evaluating the
balance between beneﬁts and risks of drugs or other health care
interventions. A BRA involves synthesizing the existing evidence
about the beneﬁts and safety of treatments from different data
sources. Data generated from rigorously designed pre- and post-
marketing studies and formal statistical analysis of those data
within the frequentist paradigm usually constitute the evidence for
risks and beneﬁts of medical treatments. The actual decisions made
by regulators, physicians, or patients about the overall risk-beneﬁt
balance, however, rely on subjective judgments and require making
implicit but inevitable trade-offs among different risks and beneﬁts
of treatments. These judgments often have a strong inﬂuence on
the decisions and yet they are prone to considerable ambiguity and
potential bias. There is a consensus that more transparent and
rigorous methods for BRA are needed [1–4].
Several recent reviews have discussed the advantages and
disadvantages of more than a dozen BRA methods [2–4].Choosing an appropriate BRA method for a given clinical ques-
tion is not straightforward. In this article, we evaluate and
compare different BRA methods on the basis of key factors of
BRA that matter most for patients [5]. This patient-centered
perspective yields a simple, uniﬁed framework for classifying
BRA methods. We formulate existing BRA methods within this
framework using common mathematical notation and use a
simple hypothetical example to illustrate their use with this
notation.Methods
Framework
Previous efforts for comparisons of BRA methods have generally
focused on technical aspects including type of data used, ana-
lytical methodology, ease of implementation, and ability to
communicate or present the results to compare different BRAociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ine, Division of Pharmacoepidemiology and Pharmacoeconomics,
, MA.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 5 0 – 2 5 9 251methods [3,4,6]. Although these criteria are important, they result
in classes of methods that share more core commonality than
previously acknowledged.
From the patient’s perspective, a BRA should be able to
measure the impact of treatment on expected quality of life.
This is possible only if the method can account for 1) probabilities
of different treatment outcomes and 2) the magnitude and
duration of impact of different treatment outcomes. The impact
of treatment on patient quality of life is not limited to clinical
outcomes (i.e., efﬁcacy or adverse effects); factors related to the
treatment process (e.g., oral vs. injection route of administration)
should be ideally incorporated into the BRA. By considering a
patient-centered perspective, BRA methods can be classiﬁed and
compared according to the extent to which they incorporate each
of these aspects. Because all BRA methods fulﬁll the ﬁrst criterion
by incorporating outcome probabilities, we propose classifying
methods in the following way according to whether and how
they account for the impact of these outcomes on the patient.
Unweighted metrics
These methods only use probabilities of outcomes (both risks and
beneﬁts) or a functional form of those probabilities in the
analysis. Neither the extent nor the duration of impact is
considered.
Metrics that incorporate patient-derived preference weights
In addition to probabilities of outcomes, methods that incorpo-
rate patient-derived preference weights can account for the
impact of different outcomes on quality of life. Weights can
reﬂect patients’ preferences for different treatment-related out-
comes and processes. In addition, some preference-weighted BRA
methods are able to incorporate the duration and timing of
different events and therefore can provide a more accurate
estimate of overall treatment impact on patients’ quality of life.
Metrics that incorporate weights from other perspectives
These methods use either a decision maker’s or other expert’s
opinion to derive a scheme to weigh different treatment out-
comes and processes. These methods can implicitly account for
the perceived impacts of different outcomes (i.e., risks and
beneﬁts) on patients’ quality of life.
Mathematical Notation
We use the following notation to formulate different BRA meth-
ods within the proposed framework. This common notation
facilitates comparisons among different BRA methods and illus-
trates the inherent similarity of methods within and across each
of the three proposed classes: pit is the probability of experiencing a beneﬁcial outcome i
with treatment t. This is expressed as the probability of having
the beneﬁcial complement of a binary outcome. For example,
if the beneﬁt is survival, pit is the probability of surviving with
treatment t. If the beneﬁt is reduction in myocardial infarction
(MI), pit is the probability of not having an MI with treatment t. qjt is the probability of experiencing a harmful outcome j with
treatment t. This is expressed as the probability of having the
harmful complement of a binary outcome. For example, if the
adverse event is mortality, qjt is the probability of dying with
treatment t. If the harm is increase in major bleeding, then qjt
is the probability of experiencing a major bleeding event with
treatment t. Δpi is the difference in probabilities (or risk difference) of the
beneﬁcial outcome i with treatment a versus treatment b; that
is, Δpi¼pia  pib. Δqj is the difference in probabilities (or risk difference) of the
harmful outcome j with treatment a versus treatment b; that
is, Δqj¼qia  qib. μ is a coefﬁcient that represents the decision maker’s thresh-
old for the relative trade-off between beneﬁts and risks. The
value μ ¼ 1 means that beneﬁts and risks are equally
important to the decision maker, whereas μ 4 1 indicates
that harms are more important. For simplicity, we assume
μ ¼ 1 in the hypothetical example.
Using this notation, we propose the following general formula
to unify a large family of existing beneﬁt-risk methods:
INB ¼ ∑
I
i¼1
viTiΔpi  μ ∑
J
j¼1
vjTjΔqj ð1Þ
where vi and Ti are the weights and duration of impact of
outcome i, respectively, on patients’ quality of life.Hypothetical Example
We use antiplatelet therapy for acute coronary syndrome to
illustrate the implementation of different BRA methods within
the proposed framework and using the above notation. The
beneﬁts of antiplatelet therapy in reducing the risk of MI and
thromboembolism have been shown in several large clinical
trials [7–11]. Antiplatelet therapy, however, is also associated
with increased risk of bleeding. Different antiplatelet agents can
have different effects on ischemic and bleeding events. This
exempliﬁes a situation in which using a BRA method can help
patients and physicians optimize their treatment decision. We
consider four relevant clinical outcomes: MI, stroke, minor
bleeding, and major bleeding. Table 1 presents the probabilities
of each outcome for two hypothetical antiplatelet drugs. In
Table 2, we present the preference weights for each health state,
measured using several different approaches. These preference
weights can reﬂect utilities measured using standard gamble
(SG), time trade-off (TTO), or indirect (e.g., EuroQol ﬁve-
dimensional questionnaire, six-dimensional health state short
form [derived from short-form 36 health survey], and health
utilities index 3) methods. We have assigned EuroQol ﬁve-
dimensional questionnaire utilities to each health state on the
basis of published studies [12–15] and present preference weights
elicited using a discrete choice experiment (DCE) [16]. We also
provide assumptions about the duration of each health state.Results
Review and Comparison of BRA Methods
In this section, we provide general mathematical formulations
for different BRA methods within each of the three proposed
categories and based on the uniﬁed equation (Equation 1). These
equations can be extended to incorporate more details (e.g., more
granular health states and timing of events) when more data are
available. We also use the hypothetical example to demonstrate
calculations using each BRA method. We provide further details
about the BRA methods in Table 3.
Unweighted Metrics
Number needed to treat and number needed to harm
Number needed to treat (NNT) represents the number of patients
that need to be treated in order for one of those patients to
beneﬁt from treatment. Number needed to harm (NNH) repre-
sents the number of patients that need to be treated in order for
Table 1 – Assumptions about probabilities of different events in the hypothetical antiplatelet example.
Event Probability (per year)* pia
† pib Δpi qja‡ qjb Δqi NNTi NNHi
Treatment a Treatment b
Myocardial infarction 5.0% 7.0% 95.0% 93.0% 2.0% – – – 50 –
Stroke 1.2% 1.4% 98.8% 98.6% 0.2% – – – 500 –
Minor bleeding 5.0% 2.5% – – – 5% 2.5% 2.5% – 40
Major bleeding 3.5% 2.5% – – – 3.5% 2.5% 1% – 100
NNH, number needed to harm; NNT, number needed to treat.
* The rates are based on the outcomes of several large clinical trials [7–11].
† pit is the probability of experiencing a beneﬁcial outcome i with treatment t. Δpi is the difference in probabilities (or risk difference) of the
beneﬁcial outcome i with treatment a vs. treatment b; i.e., Δpi ¼ pia – pib.
‡ qjt is the probability of experiencing a harmful outcome j with treatment t. Δqj is the difference in probabilities (or risk difference) of the
harmful outcome j with treatment a vs. treatment b; i.e., Δqj ¼ qja – qjb.
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NNT and NNH can be calculated as follows:
NNTi¼
1
Δpi
; NNHj¼
1
Δqj
ð2Þ
Because both NNT and NNH are counts, they can be directly
contrasted and the criterion for determining the net favorability
of treatment t assuming a beneﬁt i and risk j can be deﬁned as
follows:
NNTjNNH ¼ ∑
I
i¼1
1
NNTi
 μ ∑
J
j¼1
1
NNHj
ð3Þ
Note that NNT and NNH are inverse risk differences. Therefore,
this criterion can be alternatively formulated as follows:
NNTjNNH¼ ∑
I
i¼1
Δpi  μ ∑
J
j¼1
Δqj ð4Þ
This criterion is a special case of the general formula (Equation 1)
in which the weights, vi, and duration of impact, Ti, of different
outcomes are assumed to be 1.Table 2 – Assumptions about preference weights associa
approaches in the hypothetical antiplatelet example.
Health state Utility
weights*
(HRQOL)
Preference
weights†
(DCE)
Prefere
weigh
(DCE
u v r ¼ v/Δ
Δq
Myocardial infarction 0.84 (12) 0.18 0.0
Stroke 0.6 (13) 0.014 0.0
Minor bleeding 0.8 (15)* 0.025 0.0
Major bleeding 0.46 (14)* 0.03 0.0
DCE, discrete choice experiment; EQ-5D, EuroQol ﬁve-dimensional ques
decision analysis.
* The utility weights were multiplied by the duration of event impact to
such, the overall impact of MI and stroke is larger than that of minor and
5D utilities measured in independent studies [12–15].
† These preference weights are derived from a DCE in patients with card
‡ Weights and scores for MCDA are based on assumptions.
§ Duration of events is based on our assumptions.Minimum clinical efﬁcacy
Minimum clinical efﬁcacy is mathematically equivalent to the
NNT|NNH method. We prove this by deriving the standard
minimum clinical efﬁcacy equation from Equation 4 in Supple-
mental Materials found at http://dx.doi.org/10.1016/j.jval.2014.11.
001.
Metrics That Incorporate Preference Weights
Relative-value–adjusted NNT|NNH
Relative-value–adjusted NNT|NNH uses the NNT|NNH framework
but incorporates patients’ valuation about intensity of risk and
beneﬁt [17].
For a given beneﬁt, this relative value is expressed in the form
of RVj:
RVj¼
1  uj
1  ubase
ð5Þ
where uj is the preference weight for a health state associated
with a harmful outcome j and ubase is the preference weight
for the health state in the absence of the beneﬁcial outcome.
That is, if the beneﬁcial outcome is MI reduction, ubase
represents the health state associated with having an MI.ted with four health states derived from different
nce
ts
)
Weights using
the MCDA
method (%)‡
Scores for
the MCDA
method‡
Duration of
event
impact§
pi or
j
w ΔS ¼ Sa – Sb T
9 30 5 Lifetime
7 40 2 Lifetime
1 5 1 1 mo
3 25 3 1 mo
tionnaire; HRQOL, health-related quality of life; MCDA, multicriteria
calculate the overall effect in terms of quality-adjusted life-years. As
major bleeding, which has short duration. All utility weights are EQ-
iovascular diseases [16].
Table 3 – Classiﬁcation and comparison of existing beneﬁt-risk assessment (BRA) methods.
BRA methods Able to
incorporate
patients’
preferences?
Independent
BRA
method?*
Can statistical
uncertainty be
incorporated?
Comments Result based
on our
example
Unweighted metrics
Number needed to
treat and
number needed
to harm (NNT|
NNH)
No Yes Yes Equivalent to using inverse of
risk differences
1.3% net
probability of
beneﬁt if
treated with
a vs. b
Minimum clinical
efﬁcacy (MCE)
No Yes Yes Mathematically equivalent to
NNT|NNH and risk
difference methods
1.3% net
probability of
beneﬁt if
treated with
a vs. b
Metrics that incorporate patient-derived preference weights
Relative value–
adjusted
number needed
to treat
(RV-NNT)
Yes Yes Yes Multiple harms or multiple
beneﬁts can be included,
but not simultaneously
4.5% net
probability of
beneﬁt if
treated with
a vs. b
Maximum
acceptable risk
(MAR)
Yes Yes Yes Requires estimation using
stated preference methods
(e.g., discrete choice
experiment)
4.64% net
probability of
beneﬁt if
treated with
a vs. b
Incremental net
health beneﬁt
(INB) based on
relative-value–
adjusted life-
years (RVALYs)
Yes Yes Yes Requires estimation using
stated preference methods
(e.g., discrete choice
experiment)
3.83 RVALYs
gained per 100
patients
treated with
a vs. b
INB based on
quality-adjusted
life-years
(QALYs)
Yes Yes Yes Requires estimates of
preference weights of
different health states
using generic utility
measures (e.g., standard
gamble, time trade-off, EQ-
5D, SF-6D, and HUI)
5.43 QALYs
gained per 100
patients
treated with
a vs. b
Metrics that incorporate weights from other perspectives
Multicriteria
decision
analysis (MCDA)
Potentially yes,
if patients
determine
criteria, scores,
and weights
Yes Potentially yes,
but most MCDAs
are deterministic
Requires decision makers’
agreement on criteria,
scores, and weights
1.5 is a
dimensionless
score, only
suggesting
that a is
preferred to b
Beneﬁt-less-risk
analysis (BLRA)
Potentially yes Yes No Conceptually similar to the
MCDA method
–
Gail-NCI method Potentially yes Yes No Requires assigning weights to
the three categories of
outcomes
–
Transparent
uniform risk
beneﬁt overview
(TURBO)
Potentially yes Yes No Focuses on documenting
qualitative discussions and
judgments that take place
in a regulatory decision-
making process. Limited to
the inclusion of two risks
and two beneﬁts
–
Boers’ 3 by 3 table Potentially yes Yes No Results are in the form of a
table rather than a single
number
–
continued on next page
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Table 3 – continued
BRA methods Able to
incorporate
patients’
preferences?
Independent
BRA
method?*
Can statistical
uncertainty be
incorporated?
Comments Result based
on our
example
Other approaches cited in the literature
Quantitative
framework for
risk and beneﬁt
assessment
(QFRBA)
NA No NA Suggests using standard
epidemiological measures
(e.g., risk ratios, odds ratios,
and risk differences) for
BRA. Therefore, NNT|NNH
and MCE are examples of
QFRBA
–
(Quality-adjusted)
time without
symptoms and
toxicity (TWiST
or Q-TWiST)
Yes Yes No Same as INB using QALYs as
the outcome metric
–
Net clinical beneﬁt NA No NA Can be classiﬁed in any of the
three families of metrics
depending on the metric
that is used to quantify
risks and beneﬁts
–
Probabilistic
simulation
model (PSM)
NA No NA An approach to incorporate
uncertainty in any method
that is selected for BRA. For
example, one can use INB
using risk difference,
QALYs, or RVALYs, and
then PSM to quantify the
degree of uncertainty in
estimated INB
-
Risk-beneﬁt
contour (RBC)
Yes Yes Potentially yes A method to elicit individuals’
risk preferences and cannot
be directly used for BRA
analysis
–
Risk-beneﬁt plane
(RBP) and risk-
beneﬁt
acceptability
threshold
(RBAT)
NA No NA An approach for presenting
BRA results. One can
conduct a BRA using NNT|
NNH, QALYs, or RVALYs
and then present the
incremental risk and
incremental beneﬁt in an
RBP
–
EQ-5D, EuroQol ﬁve-dimensional questionnaire; HUI, health utilities index; NCI, National Cancer Institute; SF-6D, six-dimensional health state
short form (derived from short-form 36 health survey).
* Whether this is an explicit and distinct approach to quantify and compare beneﬁts and risks and therefore can be considered as an
independent BRA method per se. For example, Monte Carlo simulation is a method to quantify uncertainty in general terms rather than being
a standalone and independent BRA method.
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perfect health as a result of the treatment, the magnitude of
treatment effect on quality of life is 1 – ubase. The RVj ratio
indicates how patients compare the reduction in health associated
with a harmful outcome (i.e., 1 – uj) to the gain in health associated
with experiencing the beneﬁcial outcome 1 – ubase. These prefer-
ence weights can be determined using standard health-related
quality-of-life measures (e.g., SG and TTO). Once we have the RVj
for a particular harm j and beneﬁt pair, we can deﬁne the relative-
value–adjusted NNH (NNT|RV_NNH) as follows:
NNTjRV_NNH¼ 1
∑Jj¼1 RVj  Δqj
  ð6ÞNote that we can include several harmful outcomes in the
formulation of RV_NNH. This approach, however, accommodates
only a single beneﬁcial outcome. We can then compare the
RV_NNH to the NNT to determine net favorability:
NNTjRV_NNH ¼ 1
NNT
 μ 1
RV_NNH
ð7Þ
After replacing NNT and RV_NNT deﬁnitions, we have:
NNTjRV_NNH¼Δp  μ ∑
J
j¼1
RVj  Δqj
 
ð8Þ
Note that this is a special case of the general formula (Equation 1)
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harmful outcomes and using the RVj as weights, vj  Tj¼RVj
Alternatively, we could use an RV_NNT and compare it to the
unweight NNH. This would allow the incorporation of multiple
beneﬁcial outcomes but would be limited to only a single harmful
outcome. This approach is not amenable to the simultaneous
inclusion of multiple beneﬁts and harms.
Incremental net beneﬁt using maximum acceptable risk
Unlike the methods described above, the incremental net beneﬁt
(INB) approach provides a ﬂexible framework that simultaneously
accommodates probabilities and weights for multiple harms and
beneﬁts. Formulated in a uniﬁed way, the weights can be derived
using any method (e.g., SG and DCE). Maximum acceptable risk
(MAR) indicates patients’ willingness to trade off harmful and
beneﬁcial outcomes of a treatment [18] and requires eliciting
patients’ preference weights using stated preference methods
such as DCE. Assume that a DCE has been conducted in a
representative patient population and vi is the estimated prefer-
ence weight for a given change in probabilities of having a
beneﬁcial outcome i (denoted by Δpi), and vj is the estimated
preference weight for a given change in probabilities of having a
harmful outcome j (denoted by Δqi). MARij, which is the max-
imum probability of a harmful event j that individuals are willing
to accept in exchange for a 1% increase in the probability of
achieving a beneﬁcial outcome i, can be deﬁned as follows:
MARij¼
vi=Δpi
vj=Δqj
 1
100
ð9Þ
A separate MAR is calculated for each outcome in relation to one
of the outcomes (either harmful or beneﬁcial) that is selected as
the referent. These MARs can then be used to generate a single
measure of INB:
INB ¼ ∑
I
i¼1
MARiΔpi  μ ∑
J
j¼1
MARjΔqj ð10Þ
This is a special case of the general formula (Equation 1) using
MAR as weights (vi ¼ MARi) and assuming that the durations of
impact are all equal to 1.
INB using relative-value–adjusted life-years
Individuals’ relative preferences for different treatment outcomes
obtained from a DCE can be used to calculate INB in terms of
relative-value–adjusted life-years (RVALYs) [19]. Assume that rj is
the estimated preference weight for a 1% change in probability of
having a harmful outcome j; ri is the estimated preference weight
for a 1% change in probability of having a beneﬁcial outcome i; Ti
is the duration of effect of the beneﬁcial outcome i; and Tj is the
duration of effect of the harmful outcome j. The INB can then be
deﬁned as follows:
INBRVALYs ¼ ∑
I
i¼1
riTiΔpi  μ ∑
J
j¼1
rjTjΔqj ð11Þ
where rjTj and riTi are RVALYs gained or lost when experiencing
beneﬁcial or harmful events, respectively. This is a special case of
the general formula (Equation 1) assuming ri as weights (vi ¼ ri).
Preference estimates using choice experiments can evaluate
aspects of health care interventions that otherwise cannot be
captured using health-related quality-of-life measures [2]. For
instance, the use of oral medications instead of injections often
positively impacts patients’ quality of life. Yet this cannot be
captured adequately using standard health-related quality-of-life
measures. Including treatment modality as an attribute in a DCE
can quantify the impact of this aspect on patients’ preferences
and their willingness to trade off modality against efﬁcacy or
safety outcomes can be directly estimated.INB using quality-adjusted life-years
Assume that ui is the utility of a given health state after treat-
ment measured (directly or indirectly) using SG or TTO. Also,
assume that ubase is the baseline utility of patients before starting
the treatment; Ti is the duration of effect of the beneﬁcial
outcome i; and Tj is the duration of effect of the harmful outcome
j. The INB in terms of QALYs can then be deﬁned as follows:
INBQALY ¼ ∑
I
i¼1
ðubase  uiÞTiΔpi  μ ∑
J
j¼1
ðubase  ujÞTjΔqj ð12Þ
where ðubaseuiÞTi are the QALYs gained when experiencing a
beneﬁcial event and ðubaseujÞTj are the QALYs lost when expe-
riencing a harmful event.
This is a special case of the general formula (Equation 1)
assuming ðubaseuiÞ as weights ðvi¼ubaseuiÞ.
Health-related quality-of-life measures have been validated
and widely used for different health conditions, particularly in
cost-effectiveness studies. All techniques that are available for
the estimation and presentation of cost-effectiveness studies can
be directly adapted for BRA. A shortcoming of this approach,
however, is that unlike relative values obtained using DCE, it does
not consider the trade-offs that patients are willing to make
among different outcomes and it cannot capture non–health-
related outcomes (e.g., invasiveness of treatment).
Metrics That Incorporate Weights from Other Perspectives
The previous set of methods incorporate weights on the basis of
patient preferences. In particular, the INB formula is a uniﬁed
approach that enables the integration of various kinds of prefer-
ence weights. In the following section, we present a diverse set of
methods that incorporate weights that are often subjectively
determined from other perspectives.
Multicriteria decision analysis
Multicriteria decision analysis (MCDA) is a powerful tool that can be
used to facilitate joint decision making during group discussions.
MCDA can be used to organize different elements of a complex
decision, provide a systematic and transparent assessment of the
problem, and document the thought process leading to a decision in
a tractable format [20]. The ﬁrst step of an MCDA is to establish the
decision context that involves identifying key decision makers,
deﬁning the treatment options of interest, and discussing the aims
and context of the problem. The group then deﬁnes objectives and
criteria pertinent to the problem and formulates the problem as a
decision tree by organizing the objectives and criteria in a hierarchy.
Knowledge from clinical trials and safety studies can be used to
identify important beneﬁts and risks that need to be included in the
decision tree. For example, a decision tree for BRA can consist of two
branches assigned to beneﬁts and risks at the ﬁrst level, sources of
data or pivotal clinical trials at the second level, and types of
beneﬁcial or harmful events at the third level of hierarchy. Decision
makers then discuss the scores that should be given to each treat-
ment option by considering how they perform on the basis of those
certain criteria. For example, if a criterion is incidence of MI, the
probability of MI given a treatment is implicitly considered in the
scoring of that treatment. The group then agrees on weights for each
criterion that reﬂect their perceptions about its relative importance
compared with the other criteria. Finally, by calculating weighted
scores for each criterion in the decision tree, an overall weighted
score can be estimated that summarizes participants’ judgments
about the net beneﬁt of the treatment options. The results of MCDA
are in numerical format, and sensitivity analysis can be performed to
explore the effect of different scores and weights on the ﬁnal
evaluation. Nevertheless, it should be noted that scores and weights
are determined on the basis of decision makers’ judgments and
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among different beneﬁts and risks. MCDA can incorporate multiple
beneﬁts and risks in the BRA and can account for qualitative
judgment and uncertainty of the decision.
During the conduct of an MCDA, the group agrees on scores
(Sit) and weights (wi) for each treatment option criterion. The
calculation of the ﬁnal weighted score can be interpreted as an
INB of treatment a versus treatment b and using the formula
INBMCDA ¼ ∑
I
i¼1
wiΔSi  μ ∑
J
j¼1
wjΔSj ð13Þ
where ΔSi¼Sia  Sib, ΔSj¼Sja  Sjb, and ∑w¼100%:
Although the criteria might represent any number of features of
the treatments, they can be used to describe the beneﬁts and risks.
Although this approach has some similarities with the general
formula ((Equation 1), it cannot be directly derived from the general
formula. For example, ΔSi reﬂect a group’s judgment about the
magnitude of risk differences (Δpi) and their relevant importance (wi).
Beneﬁt-Less-Risk Analysis
In beneﬁt-less-risk analysis (BLRA), important harmful outcomes
associated with the treatment are identiﬁed [21]. Each patient is
then assigned a score between 0 and 3, where 0 indicates
experiencing the minimum and 3 indicates the maximum level
of harm (e.g., severity) for each outcome. Weights are assigned to
each harmful outcome on the basis of the decision maker’s
perceived weight for each of those outcomes. Outcome frequen-
cies, scores, and weights are then combined to calculate a
weighted score that reﬂects the overall risk for each treatment
option. The original BLRA method was developed to include only
one ﬁxed beneﬁcial outcome that is compared against the
calculated overall weighted risk. A parallel approach, however,
can be used to summarize multiple beneﬁts. The strength of
BLRA is that it uses patient-level data to build an aggregate
measure of INB. As with MCDA, the calculated quantities are
based on decision makers’ selection of scores and weights, rather
than on patient preferences.
Boers’ 3 by 3 Table
In this method, the investigator creates a table with three rows
for different severities of risk and three columns for different
levels of beneﬁts [22]. Similar to BLRA, this method requires
patient-level data. Each patient is categorized into one of the nine
cells on the basis of the severity of the observed treatment
outcomes. Counts in the table cells can then be transformed to
percentages. Outcome severity can be based on physician judg-
ment or patient opinion. Using physician judgment to assign
patients into different levels of risks and beneﬁts requires making
implicit and often subjective assumptions when comparing and
weighting multiple risks and beneﬁts. Finally, the results are in
the form of a table rather than a single number.
Gail/NCI Method
Gail’s method emphasizes the estimation of events within strata
deﬁned by patient characteristics (e.g., age, sex, and race) [23]. All
harmful and beneﬁcial outcomes are divided into three categories
on the basis of severity of their expected impact: life-threatening,
severe, and other (i.e., neither life-threatening nor severe). The
probabilities of different events within each category (both bene-
ﬁcial and harmful events) are then added to calculate the net risk
of life-threatening, severe, and other outcomes. A weight is
assigned to each of these three categories on the basis of the
perceived impact on the patients and a summary score is calcu-
lated. Gail’s method was originally developed to estimate risk-
beneﬁt balance on a patient level by taking into account patients’personal characteristics and relative weights for each of the three
categories of outcomes. It can be extended, however, to estimate
beneﬁt-risk balance on the population level as well. Gails’ method
can be formulated as follows:
I w1,w2,w3ð Þ¼w1 ∑
life-threatening
Δpi  ∑
life-threatening
Δqj
 !
þw2 ∑
severe
Δpi  ∑
severe
Δqj
 
þw3 ∑
other
Δpi  ∑
other
Δqj
 !
ð14Þ
where w1, w2, and w3 are the weights that are assigned to life-
threatening, severe, and other outcomes, respectively.
Transparent Uniform Risk Beneﬁt Overview
Transparent uniform risk beneﬁt overview (TURBO) considers
only two harmful outcomes and assigns a score between 1 and 5
to the more important risk and a score of 1 or 2 to the other,
comprising an R factor (i.e., “Risk factor”) of between 1 and 7 [24].
A B factor (i.e., “Beneﬁt factor”) is similarly calculated by consid-
ering the most and the second most important beneﬁts. Finally, a
T score that ranges from 1 to 7 is assigned to each patient by
subtracting his or her R factor from his or her B factor. The T
scores are based on the decision maker’s perception about the
frequency and intensity of risks or beneﬁts. For example, T ¼ 1
indicates that treatment a, when compared with treatment b, is
associated with a large risk and a small beneﬁt, whereas T ¼ 7
indicates a relatively small risk and large beneﬁt. TURBO is an
approach to document the qualitative discussions and judgments
that take place in a regulatory decision-making process.Comparing BRA Results Using Hypothetical Example
Unweighted Metrics
NNT and NNH
In Table 1, we present NNT (for MI and stroke reduction) and NNH
(for major and minor bleeding) calculated using Equation 2 for
the antiplatelet example. Using Equation 3 with m ¼ 1, we get:
NNTjNNH¼ ∑
I
i¼1
1
NNTi
 μ ∑
J
j¼1
1
NNHj
¼ 1
50
þ 1
500
 
 1
40
þ 1
100
 
¼2:2%  3:5%¼1:3%
Using risk, the difference formulation provides identical results:
NNTjNNH ¼ ∑
I
i¼1
Δpi  μ ∑
J
j¼1
Δqj¼2:2%  3:5%¼1:3%
The result, 1.3%, represents the net probability of beneﬁt if
treated with treatment a compared with treatment b. A negative
value indicates that the sum of probabilities of beneﬁts is smaller
than the sum of probabilities of risks. This method therefore
suggests an unfavorable risk- beneﬁt balance of treatment a
versus treatment b. Note that all unweighted methods implicitly
assume equal weights for all outcomes. As such, probabilities of
different outcomes are directly added or subtracted without
consideration of their relative impact on quality of life. For
example, probabilities of minor and major bleeding have been
directly summed up to represent the total probability of risks.
Metrics That Incorporate Preference Weights
Relative-Value–Adjusted NNT|NNH
In the hypothetical example, if we consider reduction in MI
(ubase ¼ 0.84) as the beneﬁt of antiplatelet therapy, then using
Equation 5 we have:
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10:8
10:84 ¼1:25 for minor bleeding
 
and
 
RVj¼
10:46
10:84 ¼3:375 for major bleeding
This implies that patients value not having a minor bleed 25% more
than they value not having an MI and they value not having a major
bleed 3.375 times more than they value not having an MI. Note that
this may be counterintuitive, but it is because the impact of minor
bleeding is assessed over only 1 month whereas the impact of MI is
assessed over a lifetime and this approach does not reconcile
differences in the duration of event impacts. Using Equation 6 for
RVNNH and Δqj for minor and major bleeding from Table 1, we have:
RV_NNH¼ 1
∑Jj¼1 Δqj  RVj
  ¼ 1
2:5% 1:25ð Þþ 1% 3:375ð Þ ¼15:38
This suggests that approximately 15 patients need to be treated with
treatment a instead of treatment b in order to have one additional
patient harmed from adverse effects of treatment a. We can then
use the RVNNH in place of the crude NNH in Equation 3 to calculate
the preference-weighted net probability of beneﬁt. Because only one
beneﬁt can be included in this method, we have chosen MI risk
reduction. Given that the NNT for MI is 50, and assuming m ¼ 1, we
have:
NNTjRV_NNH¼ 1
NNTMI
 μ 1
RV_NNH
¼ 1
50
 1
15:38
¼4:5%
This represents a 4.5% net probability of beneﬁt if treated with
treatment a compared with treatment b. The negative sign indicates
that the sum of probabilities of risks (i.e., minor and major bleeding)
exceeds the probability of beneﬁt (reducing MI), after accounting for
their relative preference weights, suggesting an unfavorable risk-
beneﬁt balance for treatment a versus b (when MI reduction is the
only beneﬁt considered).
INB Using MAR
Based on the DCE preference weights presented in Table 2 and
using major bleeding as the referent outcome, MARij can be
calculated for MI, stroke, and minor bleeding as follows:
MAR for MI versus major bleeding:
MARij¼
vi=Δpi
vj=Δqj
¼ 0:18=2%
0:03=1%
¼3
MAR for stroke versus major bleeding:
MARij¼
vi=Δpi
vj=Δqj
¼ 0:014=0:2%
0:03=1%
¼2:33
MAR for minor bleeding versus major bleeding:
MARij¼
vi=Δpi
vj=Δqj
¼ 0:025=2:5%
0:03=1%
¼0:33
Note that MAR for major bleeding versus itself is 1 by deﬁnition.
Also, note that MARij can be deﬁned for any two attributes or
outcomes, and indicates the marginal rate of substitution
between the risks of those attributes.
A 3% MAR for MI indicates that individuals in our sample, on
average, were willing to accept 3% additional risk of major
bleeding to reduce the risk of MI by 1%.
Assuming m ¼ 1, INB can be calculated using MARij as follows:
INBMAR¼ ∑
I
i¼1
MARiΔpi  μ ∑
J
j¼1
MARjΔqj
INBMAR¼ 3 2% þ 2:33 0:2%ð Þ  0:33 2:5% þ 1 1%ð Þ¼4:64%After simultaneously including all outcomes and accounting for
preferences of each, the results suggest that in a cohort of
patients using treatment a instead of treatment b, 4.64% will
experience a positive INB.
Although we have not explicitly included the duration of
events in this analysis, the scenarios and attributes of a DCE
can be designed to describe the assumptions about the impact
and duration of various outcomes. In that case, estimated
preference weights from DCE will reﬂect individuals’ preferences
for different outcomes by considering probability, impact, and
duration of treatment on quality of life.
INB Using RVALYs :
INB using RVALYs also uses preference weights estimated using
DCEs but explicitly incorporates the duration of events in the
calculation of the INB. Based on the numbers in Tables 1 and 2,
and assuming an average life expectancy of 20 years in our study
population, the INB in terms of RVALYs can be estimated using
Equation 11 as (assuming μ ¼ 1) follows:
INBRVALYs¼ ∑
I
i¼1
riTiΔpi  μ ∑
J
j¼1
rjTjΔqj
INBRVALYs¼ 0:09 20 2% þ 0:07 20 0:2%ð Þ
 0:01 1
12
 2:5% þ 0:03 1
12
 1%
 
INBRVALYs¼3:6 þ 0:28  0:0021  0:0025¼3:83%
Compared with treatment b, treatment a results in a gain of 3.83
RVALYs per 100 patient-years. Note that including the time
dimension affects the contribution of short-term risks in the
overall calculation of INB because avoiding MI or stroke is more
important than avoiding bleeding events given that MI and stroke
have long-lasting effects on patients’ quality of life.
INB Using QALYs
INB using QALYs also explicitly incorporates weights and the
duration of events in the analysis.
Applying this method to the example (assuming μ ¼ 1 yields
the following:
INBQALY¼ ∑
I
i¼1
ðu0  uiÞTiΔpi  μ ∑
J
j¼1
ðu0ujÞTjΔqj
INBQALY¼ 0:95  0:84ð Þ  20 2%þ 0:95  0:6ð Þ  20 0:2%½ 
 0:95  0:8ð Þ  1
12
 2:5%þ 0:95  0:46ð Þ  1
12
n1%
 	
INBQALY ¼ 4:4 þ 1:4ð Þ  0:031 þ 0:041ð Þ ¼ 5:43%
Assuming an average life expectancy of 20 years in the patient
population, these results suggest that using treatment a
instead of treatment b results in 5.43 additional QALYs per
100 patient-years treated. Note that health-related quality-of-
life weights often are numerically different, with preference
weights derived using DCEs. This can lead to different INB
estimates using RVALYs and QALYs methods, as is the case in
our example.
Metrics That Incorporate Weights from Other Perspectives
The unifying formula also enables INB analyses with MCDA. In
the hypothetical example, the relevant criteria for comparing the
two treatment options are risk of MI and stroke (indicating
beneﬁts) and the risk of minor and major bleeding (indicating
risks). Assuming the scores (Sit) and weights (wi) in Table 2, the
ﬁnal weighted scores can be calculated as (assuming μ ¼ 1
follows:
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I
i¼1
wiΔSi  μ ∑
J
j¼1
wjΔSj¼ 30% 5 þ 40% 2ð Þ  5% 1ð Þþ25% 3ð Þ½ ¼1:5
This implies that treatment a is net favorable to treatment b on
the basis of assumed weights and scores.Discussion
We have proposed a unifying framework for classifying BRA
methods into three families on the basis of the way in which
the methods measure and balance beneﬁts and risks. This
classiﬁcation emphasizes the aspects of BRA that are important
to patients. Metrics that incorporate patient-derived preference
weights account for the three dimensions of harms and beneﬁts
that directly affect patients’ quality of life: probability, impact,
and duration of impact of the outcomes. These methods make
explicit and transparent the trade-offs among outcomes.
Unweighted metrics, such as NNT|NNH, are commonly used for
BRA but do not capture the impact and duration of beneﬁts or
risks or patient preferences for those outcomes. Metrics that use
other weights are generally easy to implement but may not
reﬂect patient preferences.
The numerical differences in results from different BRA
methods demonstrate the impact that weights can have on the
assessments of overall balance between effectiveness and safety
of drugs. In our hypothetical example, unweighted methods
resulted in an unfavorable beneﬁt- risk balance of treatment a
versus treatment b while methods based on MAR, RVALY, and
QALY arrived at an opposite conclusion. The results of different
BRA methods can diverge in particular in situations in which
beneﬁcial and harmful outcomes differ in terms of their clinical
signiﬁcance and duration. Our hypothetical example presented a
situation in which the harmful outcomes (bleeding) had smaller
impacts on patients’ quality of life as compared with the
beneﬁcial outcomes (reduction in stroke and MI). BRA methods,
however, can yield different results under other plausible scenar-
ios. For example, if treatment a conferred a small incremental
beneﬁt and caused a rare but serious adverse event (e.g., death),
using the weighted metrics could indicate an unfavorable beneﬁt-
risk balance that might not be evident with unweighted BRA
methods.
Metrics that incorporate patient-derived preferences are
expected to produce BRA estimates that are relevant to patients.
When unweighted metrics are used, the assumption of equal
weights and duration of events should be explicitly stated.
Although metrics that use decision makers’ weights are easy to
implement, it is not clear that they will represent patient
preferences. Some studies have shown signiﬁcant differences
between patients’ and physicians’ preferences for different treat-
ment attributes [25,26]. Furthermore, BRA methods that use
decision makers’ preferences are highly dependent on the per-
ceptions and assumptions of a small group of decision makers
who participate in the study process [27]. Despite these limita-
tions, alternative BRA methods, such as MCDA, might help to
organize and clarify the thought process and underlying assump-
tions made by decision makers in BRA, particularly when direct,
rigorous measurement of patients’ preferences is not possible or
feasible.
Metrics that incorporate patient-derived preference weights
require more sophisticated approaches to elicit weights than do
those in the other families. For instance, preference weights
derived from stated preference methods (e.g., DCE) are scenario
speciﬁc. BRA using stated preference methods often requires an
initial step to elicit preferences for the attributes of interest in the
relevant population. This limits the practicability of statedpreference methods (i.e., MAR and RVALYs) compared with
preference-based methods that use generic health-related
quality-of-life weights (i.e., QALY). BRA methods based on stated
preference methods, such as DCE, however, can capture trade-
offs that patients are willing to make among different beneﬁcial
and harmful outcomes. Such trade-off information is generally
not captured by the use of health-related quality-of-life weights
(e.g., the EuroQol ﬁve-dimensional questionnaire) because they
reﬂect preferences for individual outcomes measured in distinct
studies and populations. Additional work is needed to examine
correlations between stated preferences and utility weights and
whether relative utility weights might well approximate state
preferences.
Other methods have been proposed for use in BRA [3,4].
These, however, cannot be considered as independent BRA
methods per se. For example, Monte Carlo simulation, which
has been included as a method in other BRA frameworks, is a
methodology to quantify uncertainty rather than being an
explicit approach to compare beneﬁts and risks. As such, Monte
Carlo simulation can be used in conjunction with various BRA
methods (e.g., NNT|NNH, INB using RVALYs, and INB using
QALYs) to analyze uncertainty around results. Furthermore, we
found substantial overlap in BRA methods that are often consid-
ered distinct methods in the literature [3,4]. For example, quality-
adjusted time without symptoms and toxicity and INB using
QALYs can be hardly differentiated but are generally described as
separate methods. Also, NNT and NNH are identical to using risk
difference or minimum clinical efﬁcacy methods.
Although our unifying framework is necessarily simplistic, we
believe that it will help investigators and decision makers under-
stand the major commonality among existing BRA techniques.
Others have discussed more nuanced considerations of the
desired properties of BRA methods, and these should be consid-
ered within our framework, as well. For example, Lynd et al. [6]
have proposed 10 criteria for evaluating and comparing different
BRA techniques. These criteria emphasize the ability of a BRA
technique to include individuals’ valuation of risks and beneﬁts,
uncertainty, multiple risks and beneﬁts, and duration and inten-
sity of risks and beneﬁts. They also suggest that BRA results
should be easy to interpret and the techniques should be easily
applied across different interventions with the ability to quantify
both objective and subjective risks and beneﬁts. Puhan et al. [4]
have proposed additional criteria for comparing different BRA
methods. Their criteria include type of data needed for BRA (e.g.,
individual vs. aggregate level), type of analysis (e.g., simulation
vs. empirical), type of metric (e.g., QALY, count, or probability),
ability to account for the joint distribution of harms and beneﬁts,
and type of presentation of results (e.g., differences, ratios, or
graphic methods). These considerations may be useful when
selecting among methods within a given family of metrics.
Our study has limitations. We have not conducted a formal,
systematic review of the literature on BRA methods. Rather, we
have relied on previous reviews to identify existing BRA methods
for our analysis. We supplemented these reviews with searches
for emerging BRA methods using terms such as “beneﬁt risk,”
“harm beneﬁt,” and “incremental net beneﬁt” using PubMed and
Google Scholar. Our hypothetical example presents only one
possible scenario that may arise in the context of BRA. Other
clinical examples need to be examined to compare the perform-
ance of different methods. We have used hypothetical weights
and scores for the MCDA approach to illustrate the implementa-
tion of BRA in our example. Therefore, the numerical results for
MCDA should be interpreted with caution.
Approaches to facilitate comparison and selection of BRA
techniques are increasingly important because stakeholders
around the world are focusing more attention on BRAs. For
example, the Center for Drug Evaluation and Research at the US
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 5 0 – 2 5 9 259Food and Drug Administration is working to improve communi-
cation of risks and beneﬁts [28], consider patients’ perception
about risks and beneﬁts [5], and develop a qualitative framework
for BRA [29]. Others, including the European Medicines Agency,
Canada, Australia, Switzerland, and Singapore, and the Pharma-
ceutical Research and Manufacturers of America, are also devel-
oping frameworks for qualitative and quantitative methodologies
for BRA. Examining the methods within the scope of our pro-
posed uniﬁed framework and, mathematically, using standar-
dized notation make it clear that existing methods share
substantial core commonality. It also facilitates comparisons of
the types of weights that are used across existing methods, a key
differentiating feature.
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